Showing 15 posts of 19 posts found.

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

September 14, 2023
Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …

Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients

June 8, 2023
Medical Education Echosens, Hepatology, Inventiva, liver disease, nash, non-alcoholic steatohepatitis

French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and …


Genfit’s NASH drug fails Phase 3 clinical trial

May 12, 2020
Manufacturing and Production FDA, nash

The Phase 3 trial for Genfit’s drug elafibranor has failed to improve outcomes for patients with the fatty liver disease …


Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis

November 11, 2019
Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma

The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …


Gilead’s selonsertib crashes at Phase 3 in NASH

April 26, 2019
Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib

Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …


Intercept’s NASH liver fibrosis drug shows promise at Phase 3

February 20, 2019
Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma

Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …


Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …


Roche’s Genentech to acquire inflammatory drug discovery firm Jecure

November 28, 2018
Research and Development, Sales and Marketing Genentech, Jecure, Roche, liver disease, nash, pharma

Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of …


Pfizer and Novartis partner up to develop combo therapies for NASH

October 29, 2018
Research and Development, Sales and Marketing Novartis, Pfizer, liver, nash, pharma

Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or …


Regeneron-Alnylam team up to treat NASH

March 22, 2018
Research and Development, Sales and Marketing Alnylam, Regeneron, biotech, drugs, nash, pharma, pharmaceutical

Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced …


Galectin Therapeutics’ share value plummets by half after NASH drug failure

December 6, 2017
Research and Development Galectin Therapeutics, nash, pharma, trial failure

Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis …


Top Ten most popular articles on this week

September 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten

It’s Friday, and it’s time for another round up of the most popular articles on over the last seven …


Allergan posts disappointing data in NASH

September 25, 2017
Research and Development, Sales and Marketing Allergan, biotech, drugs, nash, pharma, pharmaceutical

It was only last year that Allergan decided to cough up $1.7 billion to acquire Tobira Therapeutics, with the main …


Allergan and Novartis join forces to develop NASH combo therapy

April 18, 2017
Manufacturing and Production, Research and Development Allergan, Novartis, nash

Allergan and Novartis have announced a new partnership to conduct a clinical trial in the treatment area of non-alcoholic steatohepatitis …


Nimbus Therapeutics receives $200 million payment from Gilead

November 2, 2016
Research and Development Gilead Sciences, Nimbus Therapeutics, nash

Nimbus Therapeutics only signed a deal with Gilead Sciences back in April of this year and yet have already received …

Latest content